1. Characterization of cluster of differentiation 47 expression and its potential as a therapeutic target in esophageal squamous cell cancer.
- Author
-
Zhao, Chun-Lin, Yu, Shuang, Wang, Shu-Hui, Li, Shi-Gang, Wang, Zhi-Ju, and Han, Sheng-Na
- Subjects
ESOPHAGEAL cancer patients ,TREATMENT of esophageal cancer ,SQUAMOUS cell carcinoma ,CD47 antigen ,PHAGOCYTOSIS ,CELL lines ,IMMUNOTHERAPY - Abstract
The increased expression of cluster of differentiation (CD)47 has been identified in a number of different tumor types and is recognized as an adverse prognostic factor that indicates an increased risk of mortality in patients. The binding of CD47 to signal regulatory protein α (SIRPα) inhibits the macrophage phagocytosis of tumor cells by triggering an inhibitory 'do not eat me' signal. This is one of the mechanisms used by tumor cells to evade immune surveillance. In the present study, CD47 levels and macrophage infiltration were assessed in patients with esophageal squamous cell cancer (ESCC). CD47-overexpressing ESCC cell lines were selected and human M2 macrophage phagocytic activity was measured. The results revealed that CD47 is highly expressed and macrophages are markedly infiltrated in cancerous tissue compared with non-cancerous tissue. High CD47 expression was detected in ESCC cell lines and the results of a phagocytosis assay indicated that human M2 macrophages phagocytized tumor cells in a dose-dependent manner following the blocking of CD47-SIRPα signaling by anti-CD47 antibodies. The results of the present study therefore support the use of anti-CD47 immunotherapy to treat patients with ESCC. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF